article thumbnail

STAT+: Pharma still ‘falling short’ in providing access to low- and middle-income countries, analysis finds

STAT

Although more pharmaceutical companies are tailoring their business models to focus on low-income countries, a new analysis finds that overall industry efforts remain limited and patient access continues to suffer as a result.

article thumbnail

Opinion: Pharma’s ethically questionable sites essentially sell drugs directly to consumers

STAT

Some of the largest pharmaceutical companies in the U.S. This unprecedented move launches a new dystopic era: pharmaceutical companies as health care provider, no pesky physician middlemen needed. Want to self-prescribe a prescription drug? No problem!

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Truveta enlists health systems, drugmakers to launch ambitious new genomic database

STAT

The genetic data, cross-referenced with the patients’ de-identified medical records, will be available for purchase for researchers and life sciences companies. Pharmaceutical company Regeneron has invested $119.5

article thumbnail

Pharma’s big patent cliff, more obesity fundraising, and a failed ALS study

STAT

We chat about how pharmaceutical companies are navigating a looming patent cliff. We also talk about yet another obesity startup and a failed study from Google’s secretive anti-aging company Calico. And what are the hosts’ New Year’s resolutions? Read the rest…

article thumbnail

STAT+: FDA tells drugmakers to redo studies run by a contract research firm due to data integrity issues

STAT

During an April 2023 inspection at Raptim facilites in Nava Mumbai, India, FDA inspectors found “objectionable conditions” that led them to conclude the company falsified data in testing for multiple subjects and samples across multiple studies, according to a letter sent last week to the pharmaceutical companies.

article thumbnail

STAT+: Wyden claims Pfizer used a ‘colossal’ scheme to avoid paying billions in U.S. taxes

STAT

lawmaker described as possibly the “largest tax-dodging scheme” by a pharmaceutical company in history, Pfizer sold $20 billion in medicines to U.S. In what one U.S.

article thumbnail

STAT+: An ‘insane’ calculus: A pharma company raised price for a rare disease drug 150% to cover Medicaid rebates

STAT

Four months ago, a small pharmaceuticals company bought a medicine used to combat a rare growth disorder in children and quickly raised the list price by 150%. But the company, Eton Pharmaceuticals, argues there is no other way to keep its treatment on the market and make a profit.